Skip to Content

Belzutifan FDA Approval Status

FDA Approved: No
Generic name: belzutifan
Company: Merck
Treatment for: Renal Cell Carcinoma

Belzutifan (MK-6482) is a novel, potent and selective inhibitor of HIF-2α in development for the treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC).

Development Timeline for belzutifan

DateArticle
Mar 16, 2021Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.